Equities research analysts expect LivaNova PLC (NASDAQ:LIVN) to report sales of $274.13 million for the current quarter, according to Zacks. Three analysts have provided estimates for LivaNova’s earnings, with the lowest sales estimate coming in at $271.40 million and the highest estimate coming in at $276.00 million. LivaNova reported sales of $272.10 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 0.7%. The company is scheduled to issue its next quarterly earnings report on Wednesday, October 30th.
On average, analysts expect that LivaNova will report full year sales of $1.11 billion for the current year. For the next fiscal year, analysts forecast that the business will post sales of $1.18 billion, with estimates ranging from $1.17 billion to $1.19 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover LivaNova.
LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.03). LivaNova had a negative net margin of 23.86% and a positive return on equity of 8.56%. The company had revenue of $277.20 million for the quarter, compared to the consensus estimate of $275.14 million. During the same period last year, the company earned $0.96 earnings per share. LivaNova’s revenue for the quarter was down 3.6% compared to the same quarter last year.
In related news, CFO Thad Allen Huston sold 2,000 shares of LivaNova stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $75.00, for a total transaction of $150,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Damien Mcdonald sold 1,000 shares of LivaNova stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $73.58, for a total transaction of $73,580.00. The disclosure for this sale can be found here. In the last three months, insiders sold 5,300 shares of company stock valued at $387,999. Insiders own 0.41% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Swiss National Bank increased its position in LivaNova by 2.1% during the 2nd quarter. Swiss National Bank now owns 90,619 shares of the company’s stock worth $6,521,000 after purchasing an additional 1,900 shares in the last quarter. Comerica Bank boosted its stake in shares of LivaNova by 127.4% in the 2nd quarter. Comerica Bank now owns 72,378 shares of the company’s stock valued at $5,245,000 after purchasing an additional 40,554 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of LivaNova by 4.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 10,669 shares of the company’s stock valued at $768,000 after purchasing an additional 495 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of LivaNova by 2,237.1% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 271,100 shares of the company’s stock valued at $19,512,000 after purchasing an additional 259,500 shares during the last quarter. Finally, Wedge Capital Management L L P NC bought a new stake in shares of LivaNova in the 2nd quarter valued at $11,937,000. 84.08% of the stock is owned by institutional investors and hedge funds.
LIVN stock traded down $1.12 during midday trading on Friday, reaching $78.99. The company’s stock had a trading volume of 480,535 shares, compared to its average volume of 405,726. LivaNova has a 52 week low of $64.80 and a 52 week high of $131.54. The stock has a market capitalization of $3.88 billion, a PE ratio of 24.92, a PEG ratio of 3.44 and a beta of 0.56. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.61 and a current ratio of 0.95. The stock’s 50-day moving average price is $73.17.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Featured Article: Institutional Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.